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Abstract
The smoothened (SMO) receptor, a key signal transducer in the Hedgehog (Hh) signaling pathway
is both responsible for the maintenance of normal embryonic development and implicated in
carcinogenesis. The SMO receptor is classified as a class Frizzled (class F) G protein-coupled
receptor (GPCR), although the canonical Hh signaling pathway involves the transcription factor
Gli and the sequence similarity with class A GPCRs is less than 10%. Here we report the crystal
structure at 2.5 Å resolution of the transmembrane domain of the human SMO receptor bound to
the small molecule antagonist LY2940680. Although the SMO receptor shares the seven
transmembrane helical (7TM) fold, most conserved motifs for class A GPCRs are absent, and the
structure reveals an unusually complex arrangement of long extracellular loops stabilized by four
disulfide bonds. The ligand binds at the extracellular end of the 7TM bundle and forms extensive
contacts with the loops.
The smoothened (SMO) receptor is an essential component of the canonical Hedgehog (Hh)
signaling pathway exerting a key role in the regulation of embryonic development in
animals1,2. In vertebrates, the binding of Hh signaling protein to its receptor Patched3,4, a
12-transmbembrane protein which inhibits the activity of the SMO receptor5, results in
translocation of the SMO receptor into cilia6. In cilia, the activated SMO receptor induces
the modification of Gli transcription factors into the active form, thereby inhibiting the
processing of Gli transcription factors into a repressor form. Subsequently, active Gli
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transcription factors translocate to the nucleus activating the transcription of Gli-targeted
genes which control embryonic development and other processes2.
The SMO receptor shows a high sequence similarity with the Frizzled (FZD) receptors,
which mediate the WNT signaling pathway7,8. Both SMO and FZD receptors contain an
extracellular domain (ECD) composed of an extracellular cysteine rich domain (CRD) and a
ECD linker domain (Supplementary Fig. 1), a seven-transmembrane helices (7TM) domain,
and an intracellular C-terminal domain9. The CRD of the FZD receptors binds the
endogenous lipoglycoprotein ligands, WNTs10,11; unfortunately, the function of the
homologous SMO receptor CRD remains unclear. The 7TM domains of SMO and FZD
receptors are reminiscent of class A G protein-coupled receptors (GPCRs), although their
sequences are distinct from other GPCRs sharing less than 10% sequence identity. For this
reason and because of their distinct signaling properties, the SMO and FZD receptors have
been defined as the Frizzled class (class F)9,12.
The classification of the SMO receptor as a GPCR remains controversial principally due to
the lack of GPCR-like features in the canonical Hh signaling pathway, although emerging
evidence indicates that the SMO receptor can share some functional similarities with other
classical GPCRs13. For example, activated SMO receptor can be phosphorylated by a GPCR
kinase, leading to β-arrestin translocation and binding14. Moreover, the SMO receptor can
couple to G proteins, particularly Gi15, controlling cell migration16. Finally, the function of
the SMO receptor can be modulated by natural and synthetic small molecule agonists and
antagonists, some of which are potential anti-tumor agents17.
Structure of the SMO receptor 7TM domain
An engineered construct of the human SMO receptor with a thermostabilized
apocytochrome b562RIL (BRIL) fused to the N terminus of S190 and the C terminus
truncated at Q555, which preserved the ligand binding property of wild type human SMO
receptor, was expressed, purified, and crystallized in complex with the antagonist
LY2940680 (refs 18,19) using a lipidic mesophase method20 (Supplementary Figs. 2–4).
The structure was solved using a 3.5 Å single wavelength anomalous dispersion (SAD)
dataset, followed by extending the resolution to 2.5 Å resolution using native data collected
from five crystals (Supplementary Table 1).
The SMO receptor structure (Fig. 1) reveals a canonical GPCR 7TM-helical bundle fold
with a short helix VIII packed parallel to the membrane bilayer. The ECD linker domain and
long extracellular loops (ECLs) form intricate structures stabilized by four disulfide bonds:
C193-C213, C217-C295, C314-C390, and C490-C507. The ligand LY2940680 binds in a
pocket at the extracellular side of the receptor formed by the 7TM bundle and the ECLs. The
receptor crystallizes as a parallel dimer in the crystallographic asymmetric unit (Fig. 1 and
Supplementary Fig. 5), with the interface involving helices IV and V as observed for
CXCR4 (ref 21). It has been reported that the SMO receptor forms a functionally important
dimer, although it is unclear if the crystallographic dimer is the same as in the cell
membrane22. Since the difference between the two protomers is small (Supplementary Fig.
5), we will focus on molecule A in the following discussion for brevity, except where
otherwise noted.
7TM comparisons with class A GPCRs
Sequence similarity between the SMO receptor and class A GPCRs is very low (less than
10% sequence identity), and SMO and other class F receptors lack most of the conserved
class A motifs, including D[E]R3.50Y in helix III, CWxP6.50 in helix VI and NP7.50xxY in
helix VII. However, an overlay of the SMO receptor structure with previously solved class
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A GPCR structures shows relatively high spatial conservation of the 7TM bundle (Fig. 2a, b
and Supplementary Fig. 6). Several intracellular structural features of class A GPCR 7TM
bundles are also preserved, including a helical turn in the short intracellular loop 1 (ICL1),
and a short intracellular helix VIII running parallel to the membrane surface, although it has
distinct packing interface (residues T541, I544 and W545) with helix I (residues T251 and
A254) (Fig. 2c). Structural similarity with class A GPCRs makes transplanting the
Ballesteros and Weinstein (B&W) numbering23 system to class F receptors possible based
upon structural superposition. In each helix, the following residues are assigned number 50:
T2451.50, F2742.50, W3393.50, W3654.50, V4115.50, S4686.50, and I5307.50 (Supplementary
Figs. 1, 2 and 6). The numbering of the other residues in each helix is counted relative to the
X.50 position according to B&W numbering system23.
Despite the overall structural conservation, the 7TM fold of the SMO receptor has many
distinct features. For example, when compared with class A GPCRs the extracellular tip of
helix V is shifted towards the ligand binding cavity. Most importantly helices V, VI and VII
of the SMO receptor lack the most conserved prolines, P5.50, P6.50 and P7.50, that play
pivotal roles in the activation process of class A GPCRs. In the β2 adrenergic receptor, P5.50
has been shown to act as a local trigger of GPCR activation along with I3.40 and F6.44 (ref
24). Instead of P5.50 in helix V of class A GPCRs, the SMO receptor has P4075.46 in an
adjacent helical turn (Fig. 2d). In helix VI, P6.50 induces a kink in class A GPCRs, which
facilitates the large movement of the intracellular segment of helix VI during activation. The
SMO receptor has no proline in helix VI, and thus this helix is straighter than in class A
GPCRs (Fig. 2e). Similarly, in helix VII that typically has the conserved NPxxY motif in
class A GPCRs, the proline is also absent (Fig. 2f). Although these prolines are missing in
the SMO receptor, we observed a large number of glycines in helices V, VI and VII
(Supplementary Fig. 2). Conceivably, these glycines could facilitate both flexibility and
bending of the helices, thereby enabling 7TM packing and conformational changes during
the activation of the SMO receptor. In the current structure of the SMO receptor in complex
with an antagonist, helix VI is found in an inactive-like, closed state (Supplementary Fig. 7),
presumably precluding G-protein binding.
Binding site of LY2940680
LY2940680 is a SMO receptor antagonist designed for the treatment of solid tumors18. The
SMO receptor binding pocket has a long and narrow shape and is connected to the
extracellular aqueous environment via a small opening formed by the ECD linker domain,
ECL2 and ECL3 (Fig. 3a). This orifice likely facilitates small molecule ligand entry into the
7TM core region. Residues from the extracellular tips of helices I, II, V, and VII interact
with LY2940680, most notably R4005.39 of helix V, which hydrogen bonds with the
phthalazine ring system of the ligand. Most of the other contact residues belong to the ECD
linker domain and ECLs (Fig. 3b, c and Supplementary Fig. 8). Several structured water
molecules are identified in the ligand pocket, including two waters mediating the hydrogen
bonding network between R4005.39, H4706.52, D4736.55, E5187.38, N5217.41 side chains
(Supplementary Fig. 9). Although these waters do not directly contact LY2940680, they
may play an important role in the conformational properties and dynamics of the pocket.
Mutation of D4736.55, which participates in this water-mediated hydrogen bonding network,
to histidine results in resistance to the approved Genentech drug GDC-0449 (ref 25). Direct
contact of this residue with LY2940680 is limited (distance between the carboxylate of
D4736.55 and LY2940680 is 4.04 Å in molecule A and 4.31 Å in molecule B). Cyclopamine,
a naturally occurring steroid and the first identified small molecule SMO receptor ligand,
inhibits the Hh signaling pathway26. Radioligand assays revealed that LY2940680 and the
SMO receptor agonist SAG compete with the binding of 3H-cyclopamine (Supplementary
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Fig. 3), indicating these ligands bind within the long and narrow cavity embedded in the
7TM domain of the SMO receptor.
ECD linker domain and ECLs structures
The SMO receptor has a unique ECD linker domain and ECLs that are long compared to
most class A GPCRs. These extracellular domains are organized into complex tertiary
structures through covalent and non-covalent interactions forming a lid on the 7TM bundle
(Fig. 4a, b). The unusually long ECL1 (Fig. 4c) is connected to the ECD linker domain
through a disulfide bond between C217 and C295, which divides ECL1 into two distinctive
segments. Preceding C295, there is a short α-helical structure (G288 to V294) stabilized by
cation-π interactions between the guanidinium group of R290 and the imidazole group of
H2311.36 from helix I. After C295, ECL1 is packed into a U-shaped loop that is stabilized by
an ionic interaction between R302 and E305. In addition, this loop segment forms contacts
with the ECD linker domain through a hydrogen bonding network involving residues N202,
S205, D298 and T300. ECL2 forms a β-hairpin and connects to helix III by a disulfide bond
between C3143.25 and C390. This loop is positioned deep within the cavity formed by the
7TM bundle and makes extensive contacts with LY2940680. ECL3 is the longest loop of the
SMO receptor and forms a protrusion from the 7TM bundle into the extracellular space (Fig.
4d). The long extension of helix VI adopts a well ordered α-helical structure that is partially
stabilized by an ionic interaction between E479 and R482. This α-helical extension connects
to helix VI through a 45° non-proline kink that is stabilized by several water molecules
(Supplementary Fig. 10). On top of the ECL3 helical structure there is C490, which forms a
disulfide bond with C507. The loop between C490 and C507 is mostly disordered, while the
segment between C507 and the extracellular tip of helix VII forms an extended strand.
ECL3 also makes contact with the ECD linker domain: R485 interacts with E208 within the
ECD linker domain through a salt bridge; the amide side chain of Q491 and the guanidinium
group of R512 form hydrogen bonds with the main chain carbonyl groups of V195 and
L221, respectively. The integrity of the ECL structures is essential for maintaining the SMO
receptor in an inactive state since disruption of the extracellular structures by mutations of
the extracellular cysteines increases SMO receptor activity27.
In the extracellular region, the only structural feature that the SMO receptor shares with
class A GPCRs is the β-hairpin structure of ECL2 that is linked to the extracellular tip of
helix III via a disulfide bond (Fig 5). The corresponding cysteine in position 3.25 (B&W
numbering), is conserved in the vast majority of class A and other GPCRs. The β-hairpin
structure of ECL2 appears to be a hallmark of class A peptide-binding GPCRs21,28–33,
which has been shown by docking studies30 and peptide-receptor co-crystal structures21,31
to play an important role in the recognition of peptide ligands. The ECL2s of peptide
binding receptors all point outwards from the 7TM core domain, leaving relatively open and
spacious binding cavities for their cognate peptide ligands (Fig. 5c–f). In contrast, the β-
hairpin structure of ECL2 in rhodopsin folds on top of its covalently attached ligand retinal,
sealing the extracellular entrance of the pocket (Fig. 5b). Interestingly, the ECL2 structure of
the SMO receptor is distinct from both rhodopsin and peptide-binding GPCRs. Though
ECL2 sits much deeper in the SMO receptor than in class A peptide receptors and occupies
a substantial space in the cavity of 7TM bundle (Fig. 5a), unlike in rhodopsin, the β-hairpin
in the SMO receptor does not occlude the ligand entrance. Instead, the ECL2 of the SMO
receptor is positioned laterally to LY2940680 (Supplementary Fig. 11), forming a large part
of the binding pocket for this ligand.
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Homology with Frizzled family receptors
Within class F receptors, one can find a gapless alignment at TM helices (Supplementary
Fig. 1), and 45 residues are fully conserved within the CRD linker and 7TM domains (Fig.
6a, b). The cysteines that form disulfide bonds maintaining the structures of the ECD linker
domain and the ECLs in the SMO receptor are highly preserved in the FZD receptors (the
only exception is FZD4, of which the disulfide bond in ECL3 is missing probably due to a
very short loop), implying the importance of disulfide bonds in maintaining the ECL
structures for the FZD receptors. In the extracellular half of the 7TM bundle, the conserved
residues form a cluster of hydrophobic side chains buried between helices III (F3183.29,
Y3223.33, M3263.37), V (F4035.42, V4045.43, P4075.46), and ECL2 (V392), which is
apparently important for the structural integrity of these receptors. Closer to the intracellular
membrane boundary, there is an unusually high number of conserved tryptophans: W3313.42
and W3393.50 in helix III, W3654.50 in helix IV, and W5357.55 in helix VII. The latter
tryptophan, conserved among class F and superimposable with the location of the NPxxY
motif of class A, is shown to play an important role in receptor activation, as mutation of
W5357.55 leads to a constitutively active SMO receptor34. In the FZD receptors, the
KTxxxW motif in helix VIII is highly conserved and has been shown to be critical for the
activation of the WNT/β-catenin signaling pathway by interacting directly with
Disheveled35,36. Sequence alignment shows that the SMO receptor has an extra alanine
between lysine and threonine, but that the rest of the motif is conserved. In the SMO
receptor structure, this motif stabilizes the α-helical structure of helix VIII which packs
parallel to the membrane (Fig. 6c). The hydroxyl group of the conserved T541 of this motif
forms a hydrogen bond with the main chain carbonyl group of V536 at the intracellular end
of helix VII; while the indole nitrogen of W545 forms a hydrogen bond interaction with the
hydroxyl group of T2511.56, which is conserved in the FZD receptors. The α-helical
structure of helix VIII therefore likely plays a critical role for the interaction of activated
FZD receptors with downstream signaling proteins, such as Disheveled.
Conclusion
Evolutionarily, class F receptors precede class A receptors — as revealed by extensive
phylogenetic analysis37. Despite the earlier emergence, the diversity within class F is
significantly less than that of class A. This remarkable conservation likely reflects the
pivotal function of the SMO and FZD receptors in the regulation of cell proliferation
polarity and differentiation along with tissue formation, some of the most fundamental
physiological processes for multicellular metazoan. The SMO receptor structure highlights
the incredible use of the 7TM structural fold, with little sequence similarity to other GPCR
classes, and is a great example of structural convergence in protein space. As we learn more
about different “GPCR” classes and their structure-function, including the expansion of
many different intracellular interacting partners beyond G-proteins, it is likely the term
“GPCR” may be of limited value in describing the incredible power of the 7TM fold38 in
biology.
Methods
Generation of BRIL-ΔCRD-SMO-ΔC fusion construct for structural studies
Human SMO gene was obtained from Origene (Cat#SC122724). A thermally stabilized
apocytochrome b562 RIL from E. coli (M7W, H102I, R106L), referred to as BRIL, was
fused to the truncated N-terminus at S190 of human SMO receptor, using overlapping PCR.
The C-terminus of SMO receptor was truncated at Q555. The resulting receptor chimera
sequence was subcloned into a modified pFastBac1 vector (Invitrogen), designated as
pFastBac1-833100, which contained an expression cassette with a haemagglutinin (HA)
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signal sequence followed by a Flag tag, a 10× His tag, and a TEV protease recognition site
at the N-terminus before the receptor sequence. Subcloning into the pFastBac1-833100 was
achieved using PCR with primer pairs encoding restriction sites KpnI at the 5′ and HindIII
at the 3′ termini with subsequent ligation into the corresponding restriction sites found in the
vector.
Expression and purification of BRIL-ΔCRD-SMO-ΔC protein for crystallization
The resulting BRIL-ΔCRD-SMO-ΔC construct was expressed in Spodoptera frugiperda
(Sf9) insect cells using the Bac-to-Bac Baculovirus Expression System (Invitrogen). Sf9
cells at cell density of 2–3 × 106 cells/ml were infected with baculovirus at 27 °C. Cells
were harvested by centrifugation at 48 h post infection and stored at −80 °C until use.
Insect cell membranes were lysed by thawing frozen cell pellets in a hypotonic buffer
containing 10 mM HEPES, pH 7.5, 10 mM MgCl2, 20 mM KCl and EDTA-free complete
protease inhibitor cocktail tablets (Roche). Extensive washing of the raw membranes was
performed by repeated centrifugation (two-three times) in a high osmotic buffer comprised
of 1.0 M NaCl in the hypotonic buffer described above.
The washed membranes were resuspended into buffer containing 30 μM LY2940680
(Active Biochemicals Co. Limited), 2 mg/ml iodoacetamide (Sigma), and EDTA-free
complete protease inhibitor cocktail tablets, and incubated at 4 °C for 1 h prior to
solubilization. The membranes were then solubilized in buffer containing 50 mM HEPES,
pH 7.5, 200 mM NaCl, 1% (w/v) n-dodecyl-β-D-maltopyranoside (DDM, Anatrace), 0.2%
(w/v) cholesteryl hemisuccinate (CHS, Sigma), for 3–4 h at 4 °C. The supernatant
containing solubilized SMO protein was isolated from the cell debris by high-speed
centrifugation, and subsequently incubated with TALON IMAC resin (Clontech) overnight
at 4 °C in the presence of 20 mM imidazole and 1 M NaCl. After binding, the resin was
washed with 10 column volumes of Wash I Buffer comprised of 50 mM HEPES, pH 7.5,
800 mM NaCl, 10% (v/v) glycerol, 0.1% (w/v) DDM, 0.02% (w/v) CHS, 8 mM ATP, 20
mM imidazole, 10 mM MgCl2 and 15 μM LY2940680, followed by 6 column volumes of
Wash II Buffer comprised of 50 mM HEPES, pH 7.5, 500 mM NaCl, 10% (v/v) glycerol,
0.05% (w/v) DDM, 0.01% (w/v) CHS, 50 mM imidazole and 20 μM LY2940680. The
protein was then eluted by 3 column volumes of Elution Buffer containing 50 mM HEPES,
pH 7.5, 300 mM NaCl, 10% (v/v) glycerol, 0.03% (w/v) DDM, 0.006% (w/v) CHS, 250
mM imidazole and 50 μM LY2940680. PD MiniTrap G-25 column (GE Healthcare) was
used to remove imidazole. The protein was then treated overnight with TEV protease (His-
tagged) to cleave the N-terminal His-tag and FLAG-tag. TEV protease and cleaved N-
terminal fragment were removed by TALON IMAC resin incubation at 4 °C for 2 h. The
tag-less protein was collected as the TALON IMAC column flow-through. The protein was
then concentrated to 50–60 mg/ml with a 100 kDa cut-off Vivaspin concentrator. Protein
monodispersity was tested by analytical size-exclusion chromatography (aSEC). Typically,
the aSEC profile showed a monodisperse peak.
Lipidic cubic phase crystallization
Protein samples of the SMO receptor in a complex with LY2940680 were reconstituted into
lipidic cubic phase (LCP) by mixing with molten lipid (10%w/w cholesterol, 90%w/w
monoolein) in a mechanical syringe mixer39 at a ratio of 2/3 v/v protein solution/lipid. LCP
crystallization trials were performed using an NT8-LCP crystallization robot (Formulatrix)
as previously described40. 96-well glass sandwich plates (Marienfeld) were incubated and
imaged at 20 °C using an automated incubator/imager (RockImager 1000, Formulatrix).
Initial crystal hits were found from a precipitant condition containing 100 mM HEPES, pH
7.4, 30% (v/v) PEG400, 100 mM ammonium fluoride. After optimization, crystals grew in
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100 mM HEPES, pH 7.8, 70 mM ammonium fluoride, 32% (v/v) PEG400, 4%–8% (v/v)
Polypropylene glycol P 400 to the size of 100×20×20 μm for 2–3 d, and were harvested
using MiTeGen micromounts and flash frozen in liquid nitrogen for data collection.
Crystallographic data collection and processing
X-ray data were collected at the 23ID-D beamline (GM/CA CAT) at the Advanced Photon
Source, Argonne, IL using a 20 μm minibeam at a wavelength of 1.0330 Å and a
MarMosaic 300 CCD detector. Crystals were aligned and data were collected using strategy
similar to other GPCR structures41. Typically 20 frames at 1° oscillation and 1 s exposure
with non-attenuated beam were collected following by a translation of the crystal to a non-
exposed position or changing the crystal to minimize the effect of radiation damage. A
complete data set was obtained by indexing, integrating, scaling, and merging data from 5
crystals using HKL2000 (ref 42) (Supplementary Table 1).
Experimental phasing
The attempts to find a molecular replacement solution using all previous class A GPCR
structures as a search model did not generate any reliable solutions due to the low sequence
similarity. Therefore, experimental phasing was performed by soaking the crystals in the
presence of 5 mM tantalum bromide ([Ta6Br12]2+•2Br−, Jena Bioscience) for 24 h. The data
were collected at 23ID-D beamline (GM/CA CAT) at the Advanced Photon Source using
the peak wavelength of the tantalum L3 edge (9.880 keV). A complete 360° data set was
acquired from a single crystal by using a 20 μm minibeam at 50 × attenuation with 1°
oscillation and 1 s exposure per frame and collecting 30° wedges with direct and inverse
beam. The SAD data set was integrated and scaled at 3.5 Å resolution using HKL2000 (ref
42), and PHENIX.AutoSol43 was used to search for the heavy atom sites.
Structure determination and refinement
The structure was initial solved using 3.5 Å Ta SAD data with PHENIX.AutoSol, the map
clearly showed transmembrane helices. Further heavy atom refinement and phasing,
combining the high resolution native data and SAD (SIRAS) was carried out using
SHARP44 based on two heavy atom sites identified from the anomalous difference map.
Density modification and automatic tracing were then performed using
PHENIX.AutoBuild45. Refinement was performed by rounds of REFMAC5 (ref 46) and
autoBUSTER47 using the 2.5 Å resolution native dataset followed by manual examination
and rebuilding of the refined coordinates in the program COOT 48 using both |2Fo| - |Fc| and
|Fo| - |Fc| maps, as well as omit maps. Data collection and refinement statistics are shown in
Supplementary Table 1.
Radioligand binding assays
Radioligand binding assays used Sf9 pellets expressing the crystallization construct BRIL-
ΔCRD-SMO-ΔC (described in expression section) and crude HEK 293T membrane
preparations expressing wild type human SMO receptor in 96-well plates at a final volume
of 125 μl. To obtain crude HEK 239T membrane preparations, HEK 293T cells were
transfected with a human SMO receptor expression plasmid for 24 h and scraped into
conical centrifuge tubes. Collected cells were centrifuged at 1,000 × g for 10 min and the
cell pellet was hypotonically lysed by cold lysis buffer (50 mM Tris-HCl, pH 7.4). Crude
membrane fractions were isolated by centrifugation at 21,000 × g for 20 min at 4 °C. The
membrane pellets were resuspended with lysis buffer at 3× volume of pellet size, subjected
to protein concentration determination, and stored in aliquots at −80 °C if not used
immediately. To determine equilibrium dissociation constant (Kd) for 3H-cyclopamine, a
serial of 8 concentrations of 3H-cyclopamine (0.2 – 36 nM in triplicate) were incubated with
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6 μg of SMO Sf9 membranes or 20 μg of above SMO HEK 293T membranes in binding
buffer (50 mM HEPES, 3 mM MgCl2, EDTA-free protease inhibitor cocktail, 0.5 mg/ml
BSA, pH 7.2, modified from ref 49) for 2.5 h in dark at room temperature. Nonspecific
binding was defined by 10 μM SMO receptor antagonist LY2940680. To determine
equilibrium dissociation constant (Ki) for cyclopamine, LY2940680, and SAG (Cayman
Chemical #11914), a serial of 11 concentrations of test compound (0.1 nM to 10 μM in
triplicate sets) were incubated with a fixed concentration of 3H-cyclopamine (~Kd of 3H-
cyclopamine) and SMO Sf9 membranes or SMO HEK293 T membranes for 2.5 h in the
dark and at the room temperature. At the end of the incubation period, the reactions were
stopped by rapid filtration onto 0.3% PEI-soaked GF/A filters and washed three times with
cold PBS (pH 7.2). The filters were then microwave dried and scintillant was melted on the
filters on a hot plate. The filters were wrapped in plastic wrap and counted for radioactivity.
Results (Supplementary Fig. 3) were analyzed using GraphPad Prism 5.0.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Overall structure of the human SMO receptor 7TM domain in complex with
LY2940680
a, Overall structure of the SMO receptor bound to ligand LY2940680. The SMO receptor is
crystallized as a dimer in an asymmetric unit with molecule A colored light blue and
molecule B colored yellow. LY2940680 is shown in wheat carbon. The four disulfide bonds
are shown in orange sticks. The lipids are shown in sticks with green carbons. Membrane
boundaries are shown in dotted lines. b and c, Extracellular (EC) and intracellular (IC) view
of the SMO receptor dimer.
Wang et al. Page 11













Figure 2. Comparison of the 7TM bundle of the SMO receptor with class A GPCRs
a, Side view of superimposed structures of the SMO receptor (magenta) and class A GPCRs
(light green). b, Extracellular view of the superimposed structures. c, Superposition of ICL1
and helix VIII. The residues involved in the packing interface of helix VIII and helix I in the
SMO receptor are shown in sticks with magenta carbons. d–f, Superposition of Helix V–
VII. The P5.50, P6.50 and P7.50 residues conserved in class A GPCRs are shown in sticks. In
d, P4075.46 in the SMO receptor is shown in sticks. The α carbons of glycines in the SMO
receptor are shown as yellow spheres. Structures of class A GPCRs used (PDB accessions):
1U19, 2RH1, 2YCW, 3RZE, 3PBL, 3UON, 4DAJ, 3EML, 3V2W, 3ODU, 4DJH, 4EA3,
4DKL, 4EJ4, 3VW7, 4GRV.
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Figure 3. Ligand binding pocket for LY2940680
a, The ligand binding pocket surface is colored according to binding properties (green:
hydrophobic; blue: hydrogen-bond donor; red: hydrogen-bond acceptor). LY2940680 is
shown by sticks with magenta carbons. The membrane boundary is shown as a red line. b, |
2FO|-|FC| map (blue mesh) is shown for LY2940680 (contoured at 1.0σ, 0.10 e/ Å). Binding
pocket residues (4.0 Å cut-off distance from LY2940680) are shown in sticks with colors
indicating the location (white: TM helices; cyan: ECD linker domain; yellow: ECL1; pink:
ECL2; light blue: ECL3). The hydrogen bond interactions between R4005.39, N219 and
LY2940680 are shown as black dashed lines. c, Diagram of ligand interactions in the
binding pocket. The color scheme of the boxes for the residues is the same as b.
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Figure 4. The structure of the ECD linker domain and ECLs
a and b, Different views of the cartoon presentation of the structure of the ECD linker
domain and ECLs. ECD linker domain is colored cyan. ECL1 is colored yellow. ECL2 is
colored pink. ECL3 is colored light blue. Disulfide bonds are shown in orange sticks. c, Side
chain interactions that stabilize the structure of ECL1. The hydrogen bond network among
residues N202, S205, D298 and T300 and the ionic interaction between R302 and E305 are
shown in dashed lines. d, Side chain interactions that stabilize the structure of ELC3. The
ionic interactions between E208 and R485, E479 and R482, and hydrogen bond interaction
between Q491 and V195, R512 and L221 are shown in dashed lines.
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Figure 5. Comparison of ECL2 of the SMO receptor with class A GPCRs
a–f, Cartoon presentation of the extracellular part of the structures for (a) the SMO receptor
(white), (b) rhodopsin (PDB accession: 1U19) (dark grey), (c) CXCR4 chemokine receptor
(3ODU) (yellow), (d) κ-opioid receptor (4DJH) (light green, representing the opioid
receptor family), (e) neurotensin receptor NTSR1 (4GRV) (cyan), (f) protease activated
receptor 1 (PAR1) (3VW7) (light blue). The ECL2 of each structure is shown in magenta.
All ligands are shown in wheat. The approximate position of the extracellular membrane
boundary is shown in orange dotted lines. The disulfide bonds connecting ECL2 and helix
III are shown in orange sticks.
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Figure 6. Structural insight for the Frizzled (FZD) receptors based on their sequence homology
with the SMO receptor
a and b, Fully conserved residues in class F members are highlighted on the SMO structure.
The side chains of all these conserved residues are shown in sticks with green carbons. c,
Alignment of the KTxxxW motif in the FZD receptors to the helix VIII of the SMO
receptor. The similar α-helical structure could exist for the KTxxxW motif of the FZD
receptors which is stabilized by the hydrogen bond interactions between the hydroxyl group
of the conserved residue T541 and the main chain carbonyl group of V536, the indole
nitrogen of the conserved residue W545 and the hydroxyl group of the conserved residue
T2511.56, shown in dashed lines. The non-conserved residues are colored yellow.
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